How many stocks are there of Exelixis?
The current number of stocks of Exelixis is 321.46 M undefined.
Exelixis Stocks 2024
Exelixis Stocks
321.46 M
Ticker
EXEL
ISIN
US30161Q1040
WKN
936718
In 2024, Exelixis had 321.46 M outstanding stocks, a 0% change from the 321.46 M stocks in the previous year.
The Exelixis Stocks history
| YEAR | NUMBER OF STOCKS (undefined USD) |
|---|---|
| 2029e | 321.46 |
| 2028e | 321.46 |
| 2027e | 321.46 |
| 2026e | 321.46 |
| 2025e | 321.46 |
| 2024e | 321.46 |
| 2023 | 321.46 |
| 2022 | 324.6 |
| 2021 | 322.4 |
| 2020 | 318 |
| 2019 | 315 |
| 2018 | 312.8 |
| 2017 | 312 |
| 2016 | 250.5 |
| 2015 | 209.2 |
| 2014 | 194.3 |
| 2013 | 184.1 |
| 2012 | 160.1 |
| 2011 | 130.5 |
| 2010 | 108.5 |
| 2009 | 107.1 |
| 2008 | 105.5 |
| 2007 | 99.1 |
| 2006 | 86.6 |
| 2005 | 78.8 |
| 2004 | 72.5 |
Exelixis shares outstanding US30161Q1040 · 936718
The number of shares was Exelixis in 2023 — This indicates how many shares 321.464 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
3 years
5 years
10 years
25 Years
Max
Number of stocks
Details
Revenue, EBIT and Earnings per share
ⓘRevenue Per Share
Revenue per share represents the total revenue Exelixis earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT Per Share
EBIT per share indicates Exelixis's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income Per Share
Income per share, or earnings per share (EPS), reveals the portion of Exelixis’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected Values
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Exelixis's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
| Number of stocks | |
|---|---|
| 2004 | 72.5 M Aktien |
| 2005 | 78.8 M Aktien |
| 2006 | 86.6 M Aktien |
| 2007 | 99.1 M Aktien |
| 2008 | 105.5 M Aktien |
| 2009 | 107.1 M Aktien |
| 2010 | 108.5 M Aktien |
| 2011 | 130.5 M Aktien |
| 2012 | 160.1 M Aktien |
| 2013 | 184.1 M Aktien |
| 2014 | 194.3 M Aktien |
| 2015 | 209.2 M Aktien |
| 2016 | 250.5 M Aktien |
| 2017 | 312 M Aktien |
| 2018 | 312.8 M Aktien |
| 2019 | 315 M Aktien |
| 2020 | 318 M Aktien |
| 2021 | 322.4 M Aktien |
| 2022 | 324.6 M Aktien |
| 2023 | 321.46 M Aktien |
| 2024e | 321.46 M Aktien |
| 2025e | 321.46 M Aktien |
| 2026e | 321.46 M Aktien |
| 2027e | 321.46 M Aktien |
| 2028e | 321.46 M Aktien |
| 2029e | 321.46 M Aktien |
Exelixis Aktienanalyse
What does Exelixis do?
Exelixis Inc. is a biopharmaceutical company that specializes in researching and developing drugs for various types of cancer. The company was founded in 1994 and is headquartered in Alameda, California. It has brought several drugs to the market over the years that have had a positive impact on thousands of patients. The company's founders, Corey Goodman, George Scangos, and John Walker, previously worked at Genentech and decided to start their own company to focus on cancer research and drug development. Exelixis Inc. has had numerous successes since its inception, including the development of Cabozantinib, a drug used to treat various types of cancer such as thyroid cancer, kidney cancer, and advanced prostate cancer. The company also has several drug candidates in clinical testing. Its business model revolves around researching and developing drugs that target proteins and signaling pathways overactivated in cancer cells. Exelixis Inc. often collaborates with other companies in the pharmaceutical industry to share development costs and risks. The company is divided into different divisions to treat various cancer types, including kidney, liver, thyroid, and lung cancer. One of its significant milestones was the approval of Cabozantinib by the FDA in 2012 for the treatment of advanced kidney and thyroid cancer. The drug has since been approved in other countries and has been successful in treating different types of cancer. Exelixis Inc. is dedicated to developing better and more effective cancer drugs to help patients. It works closely with doctors, researchers, and other pharmaceutical companies to constantly explore new approaches to combat cancer cells. In summary, Exelixis Inc. is a leading player in the research and development of drugs for various types of cancer. It has a track record of approved drugs and a pipeline of innovative drug candidates. The company's goal is to help cancer patients and contribute to improving people's health. Exelixis ist eines der beliebtesten Unternehmen auf Eulerpool.com.Stocks Details
Evaluating Exelixis's Shares Outstanding
Exelixis's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.
Year-to-Year Comparison
Tracking the changes in Exelixis’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.
Impact on Investments
For investors, understanding Exelixis’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.
Interpreting Changes in Shares Outstanding
Variances in Exelixis’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.
Frequently Asked Questions about Exelixis stock
What does Number of Shares / OutstandingShares mean?
The outstanding shares (or issued shares) of Exelixis are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.
How has the number of shares of Exelixis evolved in recent years?
The number of shares of Exelixis has increased by 0% gestiegen compared to last year.
What does the number of shares mean for investors?
The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.
Why does the number of stocks fluctuate?
There are various factors that can lead to a change. Exelixis as a company can issue new shares, carry out stock splits or reverse splits.
Does the number of shares have an impact on the performance of Exelixis?
There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).
How much dividend does Exelixis pay?
Over the past 12 months, Exelixis paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Exelixis is expected to pay a dividend of 0 USD.
What is the dividend yield of Exelixis?
The current dividend yield of Exelixis is .
When does Exelixis pay dividends?
Exelixis pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Exelixis?
Exelixis paid dividends every year for the past 0 years.
What is the dividend of Exelixis?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Exelixis located?
Exelixis is assigned to the 'Health' sector.
Wann musste ich die Aktien von Exelixis kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Exelixis from 7/31/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/31/2024.
When did Exelixis pay the last dividend?
The last dividend was paid out on 7/31/2024.
What was the dividend of Exelixis in the year 2023?
In the year 2023, Exelixis distributed 0 USD as dividends.
In which currency does Exelixis pay out the dividend?
The dividends of Exelixis are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Exelixis
Our stock analysis for Exelixis Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Exelixis Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
